Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 149

1.

Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice.

Bykerk VP, Östör AJK, Alvaro-Gracia J, Pavelka K, Román Ivorra JA, Nurmohamed MT, Luder Y, Sidiropoulos PNM, Devenport J, Sibilia J.

Clin Rheumatol. 2019 Apr 26. doi: 10.1007/s10067-019-04535-z. [Epub ahead of print]

PMID:
31028551
2.

Serum visfatin levels in patients with axial spondyloarthritis and their relationship to disease activity and spinal radiographic damage: a cross-sectional study.

Hulejová H, Kropáčková T, Bubová K, Kryštůfková O, Filková M, Mann H, Forejtová Š, Tomčík M, Vencovský J, Pavelka K, Šenolt L.

Rheumatol Int. 2019 Jun;39(6):1037-1043. doi: 10.1007/s00296-019-04301-z. Epub 2019 Apr 25.

PMID:
31025138
3.

Functional Characterization of Clinically-Relevant Rare Variants in ABCG2 Identified in a Gout and Hyperuricemia Cohort.

Toyoda Y, Mančíková A, Krylov V, Morimoto K, Pavelcová K, Bohatá J, Pavelka K, Pavlíková M, Suzuki H, Matsuo H, Takada T, Stiburkova B.

Cells. 2019 Apr 18;8(4). pii: E363. doi: 10.3390/cells8040363.

4.

Cross-sectional study of patients with axial spondyloarthritis fulfilling imaging arm of ASAS classification criteria: baseline clinical characteristics and subset differences in a single-centre cohort.

Bubová K, Forejtová Š, Zegzulková K, Gregová M, Hušáková M, Filková M, Hořínková J, Gatterová J, Tomčík M, Szczuková L, Pavelka K, Šenolt L.

BMJ Open. 2019 Apr 2;9(4):e024713. doi: 10.1136/bmjopen-2018-024713.

5.

An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis.

Cohen S, Pablos JL, Pavelka K, Müller GA, Matsumoto A, Kivitz A, Wang H, Krishnan E.

Arthritis Res Ther. 2019 Mar 29;21(1):84. doi: 10.1186/s13075-019-1857-3.

6.

The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients.

Stiburkova B, Pavelcova K, Pavlikova M, Ješina P, Pavelka K.

Arthritis Res Ther. 2019 Mar 20;21(1):77. doi: 10.1186/s13075-019-1860-8.

7.

Metabolites of C-reactive protein and vimentin are associated with disease activity of axial spondyloarthritis.

Siebuhr AS, Hušaková M, Forejtová S, Zegzulková K, Tomčik M, Urbanová M, Grobelná K, Gatterová J, Bay-Jensen AC, Pavelka K.

Clin Exp Rheumatol. 2019 Feb 11. [Epub ahead of print]

PMID:
30767876
8.

S100A11 (calgizzarin) is released by circulating mononuclear cells and its elevated plasma levels distinguish systemic lupus erythematosus patients from healthy individuals.

Cerezo LA, Šumová B, Hulejová H, Štorkánová H, Szczuková L, Tomčík M, Bečvář R, Pavelka K, Vencovský J, Závada J, Šenolt L.

Clin Exp Rheumatol. 2019 Mar-Apr;37(2):338-339. Epub 2019 Feb 4. No abstract available.

9.

Prevalence and distribution of cartilage damage at the metacarpal head level in rheumatoid arthritis and osteoarthritis: an ultrasound study.

Hurnakova J, Filippucci E, Cipolletta E, Di Matteo A, Salaffi F, Carotti M, Draghessi A, Di Donato E, Di Carlo M, Lato V, Horvath R, Komarc M, Pavelka K, Grassi W.

Rheumatology (Oxford). 2019 Jan 25. doi: 10.1093/rheumatology/key443. [Epub ahead of print]

PMID:
30690561
10.

Pro-inflammatory S100A11 is elevated in inflammatory myopathies and reflects disease activity and extramuscular manifestations in myositis.

Andrés Cerezo L, Hulejová H, Šumová B, Kropáčková T, Kryštůfková O, Klein M, Mann HF, Zámečník J, Pecha O, Pavelka K, Vencovský J, Šenolt L.

Cytokine. 2019 Apr;116:13-20. doi: 10.1016/j.cyto.2018.12.023. Epub 2019 Jan 23.

PMID:
30684913
11.

Real world use of secukinumab for treatment of axial spondyloarthritis and psoriatic arthritis: nationwide results from the ATTRA registry.

Mann HF, Závada J, Šenolt L, Bubová K, Nekvindová L, Křístková Z, Horák P, Vencovský J, Pavelka K; and the ATTRA Registry.

Clin Exp Rheumatol. 2019 Mar-Apr;37(2):342-343. Epub 2019 Jan 4. No abstract available.

12.

Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries.

Lauper K, Mongin D, Iannone F, Klami Kristianslund E, Kvien TK, Nordström D, Pavelka K, Pombo-Suarez M, Rotar Z, Santos MJ, Codreanu C, Lukina G, Courvoisier DS, Gabay C.

RMD Open. 2018 Nov 5;4(2):e000809. doi: 10.1136/rmdopen-2018-000809. eCollection 2018.

13.

Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study.

Šumová B, Cerezo LA, Szczuková L, Nekvindová L, Uher M, Hulejová H, Moravcová R, Grigorian M, Pavelka K, Vencovský J, Šenolt L, Závada J.

Rheumatol Int. 2019 Mar;39(3):469-478. doi: 10.1007/s00296-018-4190-2. Epub 2018 Nov 3.

PMID:
30392117
14.

Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent.

Kristensen LE, Alten R, Puig L, Philipp S, Kvien TK, Mangues MA, van den Hoogen F, Pavelka K, Vulto AG.

BioDrugs. 2018 Oct;32(5):397-404. doi: 10.1007/s40259-018-0306-1.

15.

Lower serum clusterin levels in patients with erosive hand osteoarthritis are associated with more pain.

Kropáčková T, Šléglová O, Růžičková O, Vencovský J, Pavelka K, Šenolt L.

BMC Musculoskelet Disord. 2018 Jul 27;19(1):264. doi: 10.1186/s12891-018-2179-3.

16.

Entheseal involvement in patients with systemic lupus erythematosus: an ultrasound study.

Di Matteo A, Filippucci E, Cipolletta E, Satulu I, Hurnakova J, Lato V, De Angelis R, Horvath R, Pavelka K, Salaffi F, Grassi W.

Rheumatology (Oxford). 2018 Oct 1;57(10):1822-1829. doi: 10.1093/rheumatology/key189.

PMID:
29982722
17.

Chronic Low Back Pain: Current Pharmacotherapeutic Therapies and a New Biological Approach.

Pavelka K, Jarosova H, Sleglova O, Svobodova R, Votavova M, Milani L, Prochazka Z, Kotlarova L, Kostiuk P, Sliva J, Meroni AM.

Curr Med Chem. 2018 May 13. doi: 10.2174/0929867325666180514102146. [Epub ahead of print]

PMID:
29756567
18.

Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial.

Durez P, Pavelka K, Lazaro MA, Garcia-Kutzbach A, Moots RJ, Amital H, Govoni M, Vastesaeger N.

Clin Rheumatol. 2018 Jul;37(7):2017-2018. doi: 10.1007/s10067-018-4131-1.

PMID:
29752584
19.

Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.

Lauper K, Nordström DC, Pavelka K, Hernández MV, Kvien TK, Kristianslund EK, Santos MJ, Rotar Ž, Iannone F, Codreanu C, Lukina G, Gale SL, Sarsour K, Luder Y, Courvoisier DS, Gabay C.

Ann Rheum Dis. 2018 Sep;77(9):1276-1282. doi: 10.1136/annrheumdis-2017-212845. Epub 2018 May 5.

PMID:
29730637
20.

Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein.

Hurnakova J, Hulejova H, Zavada J, Komarc M, Cerezo LA, Mann H, Vencovsky J, Pavelka K, Senolt L.

Clin Rheumatol. 2018 Aug;37(8):2055-2062. doi: 10.1007/s10067-018-4091-5. Epub 2018 Apr 14.

PMID:
29656372

Supplemental Content

Loading ...
Support Center